Modus Therapeutics AB, owned by Dilafor AB is a development-stage biotechnology company. The company is developing treatments for patients with sickle-cell disease.In October 2022, Modus Therapeutics acquired Agile Ventures.In March 2023, Modus Therapeutics AB announced that it has secured access to bridge financing of SEK 7.0 million from Karolinska Development.In July 2021, Modus Therapeutics had completed an oversubscribed issue of units that have provided the company SEK 30 million.In July 2018, the company raised SEK 140 million (US $15.82 million) in a financing round.In June 2017, the company resolved a maximum of 1,662,300 warrants in an annual general meeting, whereby the company planned to raise SEK 83,115 (US $9,179), if all warrants were exercised for subscription of shares. The subscription of shares under the warrants might take place during the period from registration with Bolagsverket until 30 June 2020.In February 2017, the company raised